Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bridgebio Pharma Inc
(NQ:
BBIO
)
26.02
-0.17 (-0.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bridgebio Pharma Inc
< Previous
1
2
3
4
Next >
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
March 08, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
March 06, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events
March 06, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023
March 03, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
February 23, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 17, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023
February 13, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Participate in February and March Investor Events
February 08, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference
January 04, 2023
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1
December 22, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Participate in November Investor Events
November 09, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
November 03, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium
October 17, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
October 14, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society
October 13, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
October 11, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium
October 07, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial
July 26, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors
August 25, 2021
From
LianBio
Via
Business Wire
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
June 01, 2021
From
Helsinn Group
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.